RespireRx Pharmaceuticals Inc. financial data

Symbol
RSPI on OTC
Location
126 Valley Road, Suite C, Glen Rock, NJ
State of incorporation
Delaware
Fiscal year end
December 31
Former names
CORTEX PHARMACEUTICALS INC/DE/ (to 11/13/2015)
Latest financial report
10-Q - Q3 2023 - Nov 17, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 0.76 % -25.4%
Debt-to-equity -101 % +0.25%
Return On Equity 14.8 % -37.8%
Return On Assets -1.95K % +17%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 276M shares +131%
Common Stock, Shares, Outstanding 298M shares +149%
Entity Public Float 360K USD -85.5%
Common Stock, Value, Issued 298K USD +149%
Weighted Average Number of Shares Outstanding, Basic 268M shares +124%
Weighted Average Number of Shares Outstanding, Diluted 268M shares +124%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 313K USD -43.3%
General and Administrative Expense 1.1M USD -16.9%
Operating Income (Loss) -1.41M USD +24.7%
Net Income (Loss) Attributable to Parent -1.8M USD +30.6%
Earnings Per Share, Basic -0.03 USD/shares +25%
Earnings Per Share, Diluted 0 USD/shares +71.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 6.36K USD +10503%
Assets, Current 109K USD +115%
Assets 109K USD +115%
Accounts Payable, Current 6.63M USD
Employee-related Liabilities, Current 2.65M USD -15.3%
Liabilities, Current 12.1M USD +5.46%
Liabilities 12.4M USD +6.56%
Retained Earnings (Accumulated Deficit) -178M USD -1.02%
Stockholders' Equity Attributable to Parent -12.3M USD -6.09%
Liabilities and Equity 109K USD +115%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -29.2K USD -26.2%
Net Cash Provided by (Used in) Financing Activities 29.2K USD +33%
Common Stock, Shares Authorized 2B shares 0%
Common Stock, Shares, Issued 298M shares +149%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 50 USD
Interest Paid, Excluding Capitalized Interest, Operating Activities 2.34K USD +36.7%
Deferred Tax Assets, Valuation Allowance 25M USD -9.3%
Deferred Tax Assets, Gross 25M USD -9.3%
Deferred Tax Assets, Operating Loss Carryforwards 22.6M USD +14.8%
Preferred Stock, Shares Authorized 5M shares 0%
Additional Paid in Capital 164M USD +0.08%
Interest Expense 436K USD -45.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%